Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Vaccines

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 54 articles:
HTML format
Text format



Single Articles


    November 2018
  1. LARSON HJ
    The state of vaccine confidence.
    Lancet. 2018;392:2244-2246.
    PubMed     Text format    


  2. THE LANCET
    Looking beyond the Decade of Vaccines.
    Lancet. 2018;392:2139.
    PubMed     Text format    


  3. POWERS AM
    Licensed chikungunya virus vaccine: a possibility?
    Lancet. 2018 Nov 5. pii: S0140-6736(18)32809.
    PubMed     Text format    


  4. REISINGER EC, Tschismarov R, Beubler E, Wiedermann U, et al
    Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
    Lancet. 2018 Nov 5. pii: S0140-6736(18)32488.
    PubMed     Text format     Abstract available


    October 2018
  5. CLAUDE KM, Underschultz J, Hawkes MT
    Ebola virus epidemic in war-torn eastern DR Congo.
    Lancet. 2018;392:1399-1401.
    PubMed     Text format    


  6. MARKS F, Kim JH, Rakotozandrindrainy R
    Madagascar should introduce typhoid conjugate vaccines now.
    Lancet. 2018;392:1309-1310.
    PubMed     Text format    


    September 2018
  7. ZIMMER BL, Gamble L, Mayer D, Foster R, et al
    Canine rabies vaccination reduces child rabies cases in Malawi.
    Lancet. 2018;392:1115-1116.
    PubMed     Text format    


  8. PRUE G, Baker P, Graham D, Nutting C, et al
    It is time for universal HPV vaccination.
    Lancet. 2018;392:913-914.
    PubMed     Text format    


  9. BURKI T
    Cochrane review methods called into question.
    Lancet. 2018;392:906.
    PubMed     Text format    


  10. HOLT E
    41 000 measles cases in Europe since the beginning of 2018.
    Lancet. 2018;392:724.
    PubMed     Text format    


    August 2018
  11. HAYFLICK L
    Subject of The Vaccine Race offers perspective on errors.
    Lancet. 2018;392:633-634.
    PubMed     Text format    


  12. LEVY Y, Lane C, Piot P, Beavogui AH, et al
    Prevention of Ebola virus disease through vaccination: where we are in 2018.
    Lancet. 2018 Aug 10. pii: S0140-6736(18)31710.
    PubMed     Text format    


  13. THE LANCET
    Vaccine scandal and confidence crisis in China.
    Lancet. 2018;392:360.
    PubMed     Text format    


  14. GREEN A
    HPV vaccine to be offered to boys in England.
    Lancet. 2018;392:374.
    PubMed     Text format    


  15. YUAN X
    China's vaccine production scare.
    Lancet. 2018;392:371.
    PubMed     Text format    


  16. FRASER B
    Measles outbreak in the Americas.
    Lancet. 2018;392:373.
    PubMed     Text format    


    July 2018
  17. BAROUCH DH, Tomaka FL, Wegmann F, Stieh DJ, et al
    Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
    Lancet. 2018;392:232-243.
    PubMed     Text format     Abstract available


  18. PAVLAKIS GN, Felber BK
    A new step towards an HIV/AIDS vaccine.
    Lancet. 2018;392:192-194.
    PubMed     Text format    


  19. LEWNARD JA
    Ebola virus disease: 11 323 deaths later, how far have we come?
    Lancet. 2018;392:189-190.
    PubMed     Text format    


  20. DEVI S
    Setbacks in the fight to eradicate polio.
    Lancet. 2018;392:201-202.
    PubMed     Text format    


  21. BANYAI K, Estes MK, Martella V, Parashar UD, et al
    Viral gastroenteritis.
    Lancet. 2018;392:175-186.
    PubMed     Text format     Abstract available


    June 2018
  22. GREEN A
    DR Congo: investigational research against Ebola virus.
    Lancet. 2018;391:2308-2309.
    PubMed     Text format    


    May 2018
  23. WINSTON DJ, Mullane KM, Cornely OA, Boeckh MJ, et al
    Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.
    Lancet. 2018;391:2116-2127.
    PubMed     Text format     Abstract available


  24. CORCORAN B, Clarke A, Barrett T
    Rapid response to HPV vaccination crisis in Ireland.
    Lancet. 2018;391:2103.
    PubMed     Text format    


  25. MACARTNEY K, Gershon AA
    Shingles vaccine after auto-HSCT decreases risk.
    Lancet. 2018;391:2082-2084.
    PubMed     Text format    


  26. KELLY JD, Mukadi P, Dhillon RS
    Beyond vaccines: improving survival rates in the DRC Ebola outbreak.
    Lancet. 2018 May 25. pii: S0140-6736(18)31212.
    PubMed     Text format    


  27. QADRI F, Azad AK, Flora MS, Khan AI, et al
    Emergency deployment of oral cholera vaccine for the Rohingya in Bangladesh.
    Lancet. 2018;391:1877-1879.
    PubMed     Text format    


  28. AGUIAR M
    Dengue vaccination: a more ethical approach is needed.
    Lancet. 2018;391:1769-1770.
    PubMed     Text format    


  29. HARGREAVES S, Nellums LB, Ramsay M, Saliba V, et al
    Who is responsible for the vaccination of migrants in Europe?
    Lancet. 2018;391:1752-1754.
    PubMed     Text format    


    April 2018
  30. THE LANCET
    Addressing decreasing vaccine coverage in the EU.
    Lancet. 2018;391:1638.
    PubMed     Text format    


  31. CHEN S, Li J, Wang D, Fung H, et al
    The hepatitis B epidemic in China should receive more attention.
    Lancet. 2018;391:1572.
    PubMed     Text format    


    March 2018
  32. PENG X, Hu X, Salazar MA
    On reducing the risk of vaccine-associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine.
    Lancet. 2018 Mar 28. pii: S0140-6736(18)30483.
    PubMed     Text format    


  33. WATTS G
    New York Challenge sets high bar for HPV vaccination.
    Lancet. 2018;391:1137.
    PubMed     Text format    


  34. METZGER WG, Vivas-Martinez S
    Questionable efficacy of the rVSV-ZEBOV Ebola vaccine.
    Lancet. 2018;391:1021.
    PubMed     Text format    


  35. LONGINI IM, Rottingen JA, Kieny MP, Edmunds WJ, et al
    Questionable efficacy of the rVSV-ZEBOV Ebola vaccine - Authors' reply.
    Lancet. 2018;391:1021-1022.
    PubMed     Text format    


    February 2018
  36. PANG T, Gubler D, Goh DYT, Ismail Z, et al
    Dengue vaccination: a more balanced approach is needed.
    Lancet. 2018;391:654.
    PubMed     Text format    


  37. LARSON HJ
    A global girl gang.
    Lancet. 2018;391:527-528.
    PubMed     Text format    


  38. PAULES CI, Subbarao K
    Influenza vaccination and prevention of cardiovascular disease mortality - Authors' reply.
    Lancet. 2018;391:427-428.
    PubMed     Text format    


  39. CALDEIRA D, Ferreira JJ, Costa J
    Influenza vaccination and prevention of cardiovascular disease mortality.
    Lancet. 2018;391:426-427.
    PubMed     Text format    


  40. THE LANCET
    Yellow fever: a major threat to public health.
    Lancet. 2018;391:402.
    PubMed     Text format    


    January 2018
  41. THE LANCET
    Preparing for seasonal influenza.
    Lancet. 2018;391:180.
    PubMed     Text format    


  42. THE LANCET
    A new vaccine for typhoid control.
    Lancet. 2018;391:96.
    PubMed     Text format    


  43. PETOUSIS-HARRIS H, Paynter J, Morgan J, Saxton P, et al
    Pitfalls of the healthy vaccinee effect - Authors' reply.
    Lancet. 2018;391:123-124.
    PubMed     Text format    


  44. MAHMUD SM, Righolt CH
    Pitfalls of the healthy vaccinee effect.
    Lancet. 2018;391:123.
    PubMed     Text format    


  45. ZAFFRAN M, McGovern M, Hossaini R, Martin R, et al
    The polio endgame: securing a world free of all polioviruses.
    Lancet. 2018;391:11-13.
    PubMed     Text format    


    December 2017
  46. MARQUES ETA, Burke DS
    Tradition and innovation in development of a Zika vaccine.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33107.
    PubMed     Text format    


  47. GAUDINSKI MR, Houser KV, Morabito KM, Hu Z, et al
    Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33105.
    PubMed     Text format     Abstract available


  48. MODJARRAD K, Lin L, George SL, Stephenson KE, et al
    Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33106.
    PubMed     Text format     Abstract available


    October 2017
  49. YIN Y
    HPV vaccination in China needs to be more cost-effective.
    Lancet. 2017;390:1735-1736.
    PubMed     Text format    


    September 2017
  50. JIN C, Gibani MM, Moore M, Juel HB, et al
    Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
    Lancet. 2017 Sep 28. pii: S0140-6736(17)32149.
    PubMed     Text format     Abstract available


  51. FEASEY NA, Levine MM
    Typhoid vaccine development with a human challenge model.
    Lancet. 2017 Sep 28. pii: S0140-6736(17)32407.
    PubMed     Text format    


  52. HUH WK, Joura EA, Giuliano AR, Iversen OE, et al
    Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
    Lancet. 2017 Sep 5. pii: S0140-6736(17)31821.
    PubMed     Text format     Abstract available


  53. DENNY L
    Nine-valent human papillomavirus vaccine: great science, but will it save lives?
    Lancet. 2017 Sep 5. pii: S0140-6736(17)32144.
    PubMed     Text format    


    November 2016
  54. DENNY L, de Sanjose S, Mutebi M, Anderson BO, et al
    Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries.
    Lancet. 2016 Nov 1. pii: S0140-6736(16)31795.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: